{"id":519721,"date":"2021-07-29T07:08:02","date_gmt":"2021-07-29T11:08:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/"},"modified":"2021-07-29T07:08:02","modified_gmt":"2021-07-29T11:08:02","slug":"imv-to-participate-in-the-btig-virtual-biotechnology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/","title":{"rendered":"IMV to Participate in the BTIG Virtual Biotechnology Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>IMV to Participate in the BTIG Virtual Biotechnology Conference<\/b><\/p>\n<p>DARTMOUTH, Nova Scotia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIMV Inc. (\u201cIMV\u201d or the \u201cCorporation\u201d) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV\u2019s executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIG\u2019s research team.\n<\/p>\n<p>\nBTIG Virtual Biotechnology Conference Fireside Chat:<br \/>\n<br \/>Tuesday, August 10 at 11:00 am (ET)\n<\/p>\n<p>\nA link to this presentation will be available under \u201c<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.imv-inc.com%2Fevents-and-presentations&amp;esheet=52467890&amp;newsitemid=20210729005153&amp;lan=en-US&amp;anchor=Events%2C+Webcasts+and+Presentations&amp;index=1&amp;md5=e6c8a65eec061954abdc43da9af6897b\">Events, Webcasts and Presentations<\/a>\u201d in the investors section of IMV\u2019s website at the above-mentioned time and for approximately 30 days thereafter.\n<\/p>\n<p><strong>IMV Forward-Looking Statements<\/strong><\/p>\n<p>\nThis press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as \u201cwill\u201d, \u201cmay\u201d, \u201cpotential\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201ccontinue\u201d, \u201canticipate\u201d and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the Company\u2019s ability to advance its development strategy, as well as the prospects, for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, the ability to access capital, the successful and, generally, the timely completion of clinical trials and studies and the receipt of all regulatory approvals as well as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV\u2019s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=52467890&amp;newsitemid=20210729005153&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=2&amp;md5=3cf1d430b07057e9c594ea5a8928af2a\">www.sedar.com<\/a> and on EDGAR at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2Fedgar&amp;esheet=52467890&amp;newsitemid=20210729005153&amp;lan=en-US&amp;anchor=www.sec.gov%2Fedgar&amp;index=3&amp;md5=f03f04b10d10517b52e91bbde5c92e07\">www.sec.gov\/edgar<\/a><\/p>\n<p><b>About IMV<\/b><\/p>\n<p>\nIMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing hard-to-treat cancer and other unmet medical needs. IMV is pioneering a novel class of cancer immunotherapies based on the Company\u2019s proprietary delivery platform (DPX). This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects. IMV\u2019s lead candidate, maveropepimut-S (formerly named DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing maveropepimut-S in breast and advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual targeted immunotherapy to be evaluated in subjects with bladder cancer later this year. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.imv-inc.com&amp;esheet=52467890&amp;newsitemid=20210729005153&amp;lan=en-US&amp;anchor=www.imv-inc.com&amp;index=4&amp;md5=4747dd4124a4c6396dd9d74c9cb18a71\">www.imv-inc.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fimv_inc&amp;esheet=52467890&amp;newsitemid=20210729005153&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=3ed4831fc92a0a55f33fb7924b6a2b47\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fimv-inc%2F&amp;esheet=52467890&amp;newsitemid=20210729005153&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=4483c85fb7cce4e2d8e241a82b3cea6b\">LinkedIn<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210729005153\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210729005153\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations<br \/>\n<br \/><\/b><br \/><b>Marc Jasmin, Senior Director, Investor Relations, IMV<br \/>\n<\/b><br \/>O: (902) 492-1819, ext: 1042<br \/>\n<br \/>M: (514) 617-9481 E: <a rel=\"nofollow\" href=\"mailto:mjasmin@imv-inc.com\">mjasmin@imv-inc.com<br \/>\n<\/a><\/p>\n<p><b>Irina Koffler, Managing Director, LifeSci Advisors<br \/>\n<\/b><br \/>O: (646) 970-4681M: (917) 734-7387<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:ikoffler@lifesciadvisors.com\">ikoffler@lifesciadvisors.com<br \/>\n<\/a><\/p>\n<p><b>Media<br \/>\n<br \/><\/b><br \/><b>Delphine Davan, Senior Director of Communications, IMV<br \/>\n<\/b><br \/>M: (514) 968-1046<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:ddavan@imv-inc.com\">ddavan@imv-inc.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Stem Cells Pharmaceutical Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>IMV to Participate in the BTIG Virtual Biotechnology Conference DARTMOUTH, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; IMV Inc. (\u201cIMV\u201d or the \u201cCorporation\u201d) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV\u2019s executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIG\u2019s research team. BTIG Virtual Biotechnology Conference Fireside Chat: Tuesday, August 10 at 11:00 am (ET) A link to this presentation will be available under \u201cEvents, Webcasts and Presentations\u201d in the investors section of IMV\u2019s website at the above-mentioned time and for approximately 30 days thereafter. IMV Forward-Looking Statements &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMV to Participate in the BTIG Virtual Biotechnology Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519721","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMV to Participate in the BTIG Virtual Biotechnology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMV to Participate in the BTIG Virtual Biotechnology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IMV to Participate in the BTIG Virtual Biotechnology Conference DARTMOUTH, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; IMV Inc. (\u201cIMV\u201d or the \u201cCorporation\u201d) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV\u2019s executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIG\u2019s research team. BTIG Virtual Biotechnology Conference Fireside Chat: Tuesday, August 10 at 11:00 am (ET) A link to this presentation will be available under \u201cEvents, Webcasts and Presentations\u201d in the investors section of IMV\u2019s website at the above-mentioned time and for approximately 30 days thereafter. IMV Forward-Looking Statements &hellip; Continue reading &quot;IMV to Participate in the BTIG Virtual Biotechnology Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T11:08:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMV to Participate in the BTIG Virtual Biotechnology Conference\",\"datePublished\":\"2021-07-29T11:08:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/\"},\"wordCount\":675,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/\",\"name\":\"IMV to Participate in the BTIG Virtual Biotechnology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-29T11:08:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMV to Participate in the BTIG Virtual Biotechnology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMV to Participate in the BTIG Virtual Biotechnology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/","og_locale":"en_US","og_type":"article","og_title":"IMV to Participate in the BTIG Virtual Biotechnology Conference - Market Newsdesk","og_description":"IMV to Participate in the BTIG Virtual Biotechnology Conference DARTMOUTH, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; IMV Inc. (\u201cIMV\u201d or the \u201cCorporation\u201d) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV\u2019s executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIG\u2019s research team. BTIG Virtual Biotechnology Conference Fireside Chat: Tuesday, August 10 at 11:00 am (ET) A link to this presentation will be available under \u201cEvents, Webcasts and Presentations\u201d in the investors section of IMV\u2019s website at the above-mentioned time and for approximately 30 days thereafter. IMV Forward-Looking Statements &hellip; Continue reading \"IMV to Participate in the BTIG Virtual Biotechnology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T11:08:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMV to Participate in the BTIG Virtual Biotechnology Conference","datePublished":"2021-07-29T11:08:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/"},"wordCount":675,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/","name":"IMV to Participate in the BTIG Virtual Biotechnology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-29T11:08:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210729005153r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imv-to-participate-in-the-btig-virtual-biotechnology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMV to Participate in the BTIG Virtual Biotechnology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519721"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519721\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}